American Bio Medica (American Bio Medica) EBIT : $1.02 Mil (TTM As of Mar. 2023)

View and export this data going back to . Start your Free Trial

What is American Bio Medica EBIT?

American Bio Medica's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2023 was $1.90 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2023 was $1.02 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. American Bio Medica's annualized ROC % for the quarter that ended in Mar. 2023 was -52.64%. American Bio Medica's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was 3,176.62%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. American Bio Medica's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was 909.82%.

American Bio Medica EBIT Historical Data

The historical data trend for American Bio Medica's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Bio Medica EBIT Chart

American Bio Medica Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

-0.74

-0.42

-0.62

-0.27

-1.21

American Bio Medica Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
EBIT	Get a 7-Day Free Trial															-0.33	-0.35	-0.26	-0.28	1.90

Competitive Comparison of American Bio Medica's EBIT

For the Diagnostics & Research subindustry, American Bio Medica's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

American Bio Medica's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, American Bio Medica's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where American Bio Medica's EV-to-EBIT falls into.

American Bio Medica EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.02 Mil.

American Bio Medica (OTCPK:ABMC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

American Bio Medica's annualized ROC % for the quarter that ended in Mar. 2023 is calculated as:

	ROC % (Q: Mar. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2022 )	+	Invested Capital (Q: Mar. 2023 ))	/ count )
=	-0.848 * ( 1 - 0% )	/	( (2.933	+	0.289)	/ 2 )
=	-0.848	/	1.611
=	-52.64 %

where

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.269	-	1.169	-	( 0.034	-	max(0, 3.602	-	0.769	+	0.034	))
=	2.933

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.659	-	0.828	-	( 0.068	-	max(0, 1.117	-	0.659	+	0.068	))
=	0.289

Note: The Operating Income data used here is four times the quarterly (Mar. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

American Bio Medica's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2022		Q: Mar. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	7.608	/	( ( (0.479 + max(-0.835, 0))	+	(0 + max(-0.553, 0)) )	/	2 )
=	7.608	/	( ( 0.479	+	0 )	/	2 )
=	7.608	/	0.2395
=	3,176.62 %

where Working Capital is:

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.082	+	0.379	+	0.072)	-	(1.169	+	0.109	+	0.09)
=	-0.835

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.089	+	0	+	0.3)	-	(0.828	+	0.114	+	0)
=	-0.553

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

American Bio Medica's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2023 )
	=	1.019	/	0.112
	=	909.82 %

American Bio Medica EBIT Related Terms

Thank you for viewing the detailed overview of American Bio Medica's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

American Bio Medica (American Bio Medica) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » American Bio Medica Corp (OTCPK:ABMC) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

122 Smith Road, Kinderhook, New York, NY, USA, 12106

Website

https://www.abmc.com

American Bio Medica Corp is a us-based company engaged in manufacturing and selling lateral flow immunoassay tests, primarily for the immediate detection of certain drugs in urine and oral fluids at the point of collection. It also manufactures and sells drug testing products and provides bulk test strip manufacturing services to unaffiliated third parties on a contract basis. The company offers few urine tests which include Rapid Drug Screen, RDS InCup, Rapid TOX, and Rapid TOX Cup II. Its target customer includes workplace, government, corrections, clinical and educational markets. Geographically, it derives a majority of revenue from the United States.

Executives

Stuart Steinberg	10 percent owner	85 BELLEVUE AVENUE, RYE NY 10580
John J Moroney	10 percent owner	118 PEGASUS DR., JUPITER FL 33477
Chaim Davis	director	2601 PINE TREE DRIVE, MIAMI BEACH FL 33140
Peter Jerome	director	7 RIDGECREST AVE, LATHAM NY 12110
Diane Generous	director	122 SMITH ROAD, KINDERHOOK NY 12106
Melissa A Waterhouse	officer: EVP, CCO, CORP SEC	AMERICAN BIO MEDICA CORPORATION, 122 SMITH ROAD, KINDERHOOK NY 12106
Mp Biomedicals Llc	10 percent owner	3 HUTTON CENTRE DRIVE, SUITE 100, SANTA ANA CA 92707
Douglas Casterlin	officer: Executive Vice President	C/O MELISSA A. WATERHOUSE/ABMC, 122 SMITH ROAD, KINDERHOOK NY 12106
Jean Neff	director	C/O ABMC, 122 SMITH ROAD, KINDERHOOK NY 12106
Stefan Parker	officer: Chief Financial Officer	122 SMITH ROAD, KINDERHOOK NY 12106
Carl A Florio	director	C/O HUDSON RIVER BANK & TRUST CO, PO BOX 76, HUDSON NY 12534
Stan Cipkowski	director	300 S LAKE DR, STE 340, FISHKILL NY 12553
Anthony G Costantino	director	122 SMITH ROAD, KINDERHOOK NY 12106
Edmund M Jaskiewicz	director, officer: President
Richard Koskey	director	C/O ABMC 122 SMITH ROAD, 122 SMITH ROAD, KINDERHOOK NY 12106